The introduction of PD-L1 via treatment with a PD-L1-Ig fusion protein in in vitro human studies as well as in vivo MS mouse models led to disease improvement via the suppression of self-recognizing and active immune cells, promoting a tolerogenic phenotype (reviewed by [34]). The gene discussed is CD274; the disease is myeloid sarcoma.